In a Law360 article, health care partner Margaux Hall discussed the U.S. Centers for Medicare and Medicaid revised guidance for Medicare drug inflation rebates that addresses how it calculates rebates for drug shortages and announced that 48 drugs are subject to the pricing rebates.
Margaux said the CMS revised guidance seems to avoid some of the potential consequences of "too blunt an approach" to the rebates and the potential they could further "exacerbate drug shortage and supply chain issues" that would make drugs less available to Americans. She notes the agency's revisions somewhat soften, but don't completely remove, these potential adverse impacts.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.